ProShare Advisors
CTXR icon

ProShare Advisors’s Citius Pharmaceuticals CTXR Stock Holding History

ProShare Advisors’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-721
Closed -$10.5K – 2084
2024
Q2 		$10.5K Sell
721
-246
-25% -$4.41K ﹤0.01% 1834
2024
Q1 		$21.7K Buy
967
+153
+19% +$2.79K ﹤0.01% 1969
2023
Q4 		$15.4K Buy
814
+175
+27% +$3.32K ﹤0.01% 1932
2023
Q3 		$10.9K Hold
639
– – ﹤0.01% 1803
2023
Q2 		$19.2K Buy
+639
New +$21K ﹤0.01% 1835
2022
Q2 		– Sell
-929
Closed -$42K – 1867
2022
Q1 		$42K Sell
929
-63
-6% -$2.49K ﹤0.01% 2125
2021
Q4 		$38K Buy
992
+410
+70% +$18.6K ﹤0.01% 2311
2021
Q3 		$30K Sell
582
-596
-51% -$29.9K ﹤0.01% 1989
2021
Q2 		$103K Buy
+1,178
New +$70.8K ﹤0.01% 2289

Other funds holding CTXR

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
CCC
Chelsea Counsel Company Los Angeles, California $225M AUM 45.99% 1-Year Est. Return

ProShare Advisors's CTXR Position: Q3 2024 in Review

ProShare Advisors sold out of Citius Pharmaceuticals (CTXR) in Q3 2024, closing a stake of 721 shares — an estimated $10.5K sold.

ProShare Advisors first reported a position in CTXR in Q2 2021 and held it in 9 quarters. The position peaked at $103K in Q2 2021. 57 funds tracked by Wall St. Rank hold CTXR as of Q3 2024.

  • ProShare Advisors reported no remaining Citius Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • ProShare Advisors sold 721 Citius Pharmaceuticals shares in Q3 2024, an estimated $10.5K.
  • ProShare Advisors first reported a position in Citius Pharmaceuticals in Q2 2021 and held it in 9 quarters.
  • ProShare Advisors's Citius Pharmaceuticals position peaked at $103K in Q2 2021.
  • 57 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q3 2024.

Based on ProShare Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.